The Raynaud’s Association, a 501(c)3 non-profit health organization, is launching a new and assertive campaign – “Don’t Turn a Cold Shoulder to Painful Fingers” – to urge those with the painful disorder – and their doctors – not to dismiss the pain Raynaud’s sufferers endure.
October is Raynaud’s Awareness Month, when temperatures generally get chillier and an estimated 5-10 percent of the population experiences numbness and pain in their fingers, toes and other extremities. Stress can also trigger the condition.
To view the multimedia release go to:
https://www.multivu.com/players/English/8396551-raynauds-association-october-raynauds-awareness-month/
Every spring, allergies take control of the lives of millions of Americans, affecting their work, their family time and even how well they sleep at night. Something else affects those millions of allergy sufferers, according to a new survey: big misconceptions about allergies that may keep people from getting needed relief.
To help put those misconceptions about allergies to rest, Sanofi is teaming up with science educator and television personality Adam Savage, along with allergist Dr. Neeta Ogden, to dispel them with credible information. The goal: help the 50 million allergy sufferers in America get the facts they need to understand and treat their allergies and take back control of their lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8255452-sanofi-allergy-misconceptions-facts-adam-savage/
Sanofi Consumer Healthcare – the makers of new Xyzal® Allergy 24HR, which is now available on retail shelves nationwide – revealed today the results of a social experiment in which 160 participants (80 allergy sufferers and 80 non-sufferers) wore a wearable device for 30 days to track their sleep and activity. The first-of-its-kind experiment found allergy symptoms can impact various elements of sufferers’ lives, including both the quality of their sleep and their daytime activities. Xyzal is partnering with renowned allergist Dr. Neeta Ogden to encourage allergy sufferers to Wise Up about the importance of managing their allergies this spring, so they can have a better night’s sleep and Rise Up in the morning to take on the day.
To view the multimedia release go to:
https://www.multivu.com/players/English/8029451-sanofi-xyzal-allergy-social-experiment-wise-up-rise-up/
Rowenta, maker of the revolutionary new air purifier the Intense Pure Air, is collaborating with renowned Environmental Toxicologist Dr. Noreen Khan-Mayberry (aka “The Tox Doc”), to help allergy sufferers better manage their symptoms. An estimated 50 million Americans are allergic to dust, dander, mold and mites, which can cause trouble breathing, excessive sneezing, eye irritation and coughing, amongst other ailments.
Seasonal allergies affect approximately 30% of U.S. residents and are worsening due to climate change, which is not only causing an increase in pollen levels, but also extending the length of pollen season. As such, allergy sufferers and people with asthma and other respiratory issues are at an even greater risk for heightened symptoms both indoors and outdoors.
To view the multimedia release go to:
http://www.multivu.com/players/English/7779051-rowenta-intense-allergen-air-purifier/
Extremely painful and destructive, gout is the most common form of inflammatory arthritis with elevated serum uric acid (sUA) a root cause of the disease. Even with the growing incidence of gout, recent research from the Gout & Uric Acid Education Society (GUAES) found that just 16 percent of Americans overall know the target sUA number for gout (6 mg/dL or below) – and just 38 percent of people with gout had their sUA levels checked within the past six months, the timeframe recommended by the American College of Rheumatology. Additionally, the majority of gout sufferers don’t understand the importance of taking daily uric acid-lowering medications, with four in 10 incorrectly believing that they can stop taking medications when they aren’t experiencing flares.
Seeking to increase recognition of the severity of gout and need for routine sUA testing and management, GUAES hosted a professional roundtable discussion on October 3, 2015. The roundtable brought together several experts – rheumatologists, a family care physician, and representatives from the American Association of Diabetes Educators, the National Kidney Foundation and CreakyJoints – to explore how to more effectively educate about gout and improve access to public education and treatment.
To view the multimedia release go to:
http://www.multivu.com/players/English/7715851-guaes-gout-roundtable-discussion/
It’s normal to have uric acid in your body, but too much can increase your risk for gout – an extremely painful form of inflammatory arthritis that often presents with other health issues, including kidney disease, heart disease, diabetes and permanent joint and tissue damage. Despite this, just 10 percent of gout sufferers are being properly treated – and more than one-third have not had their uric acid checked in the past five years.
To raise awareness about the need for timely treatment for gout – including regular monitoring of serum uric acid (sUA) levels – the Gout & Uric Acid Education Society (GUAES) has introduced a new “Go for Six” campaign. The campaign urges those who have or who are at risk for gout to get their sUA levels checked every six months, and to work with their doctor to determine a treatment plan for controlling gout and keeping sUA levels to a healthy 6 mg/dL or below.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7420351-gout-uric-acid-go-for-six-campaign/
Eight out of 10 people will be affected by back pain at some point during their lives, making it the No. 1 cause of disability worldwide and resulting in as much as $200 billion in lost wages and productivity. Many sufferers struggle for years to find relief, but treatment options often only provide short-term relief or, in the case of pain medication, carry serious side effects, including drowsiness, liver damage and potential for addiction. Now, thanks to Hocoma, a leader in the development of robotic and sensor-based medical devices for functional movement therapy, consumers have a new way to improve and sustain low back health in the comfort of their own home.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7370551-hocoma-innovative-medical-device-therapeutic-gaming-technology-valedo-low-back-health/
Entering its 10th year of providing gout education, the Gout & Uric Acid Education Society (GUAES) is amplifying its efforts on May 22 – National Gout Awareness Day – and encouraging gout sufferers to seek immediate and ongoing treatment. Information and resources are available to both the general public and medical professionals through the organization’s new website, found at GoutEducation.org.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7134051-gout-and-uric-acid-education-society-national-gout-awareness-day
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope. While several leading cancer centers have only begun introducing immunotherapy, Issels has been a leader in Integrative Immunotherapy for decades.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7224051-issels-integrative-immunotherapy-lung-cancer-advanced-treatment
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65511-issels-integrative-immunotherapy-non-toxic-treatment-lung-cancer
Lung cancer is the most common cause of cancer-related death worldwide, with the highly malignant small cell lung cancer having the worst prognosis. In recent years the surge of immunotherapy has given cancer sufferers new hope.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/64826-issels-recurrent-lung-cancer-responds-to-integrative-immunotherapy
The Asthma and Allergy Foundation of America (AAFA) and Teva Respiratory released results today from a new survey which showed that more than half (59 percent) of nasal allergy sufferers polled reported sleep issues as a result of their allergy symptoms, yet only 35 percent proactively treat their nasal allergy symptoms. Furthermore, nearly half of those surveyed (48 percent) said their nasal allergy symptoms, such as nasal congestion and sneezing, also interrupted their partner’s sleep.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60975-teva-respiratory-aafa-ditch-the-drip-misty-may-treanor-nasal-allergies
